Rocaglaol

Rocaglaol
Product Name Rocaglaol
CAS No.: 147059-46-9
Catalog No.: CFN99609
Molecular Formula: C26H26O6
Molecular Weight: 434.5 g/mol
Purity: >=98%
Type of Compound: Phenols
Physical Desc.: Powder
Targets: Bcl-2/Bax | TNF-α | AP-1 | NF-kB | Cdc2
Source: The herbs of Aglaia odorata Lour
Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Price:
Rocaglaol is a potent anticancer drug that induces apoptosis of LNCaP cells through the mitochondrial pathway and its G2/M-phase cell cycle arrest is associated with the down-regulation of Cdc25C and the dephosphorylation of Cdc2. Rocaglaol can reduce tissue inflammation and neuronal cell death by inhibiting NF-kappa B and AP-1 signaling, resulting in significant neuroprotection in animal models of neurodegeneration. Rocaglaol derivatives can prevent or to limit the cardiotoxicity of an antineoplastic agent, in particular to prevent or to limit the apoptosis of cardiomyocytes induced by such agent. Rocaglaol, pyrimidinone and aglaiastatin are potent inhibitors of the growth of K--cells, with IC50 values of 1-10 ng/mL, and induce normal morphology in K--cells at 10-30 ng/mL, they also specifically inhibit protein synthesis.
Inquire / Order: manager@chemfaces.com
Technical Inquiries: service@chemfaces.com
Tel: +86-27-84237783
Fax: +86-27-84254680

Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
  • JMicrobiol Biotech Food Sci2021, e4289.
  • An Acad Bras Cienc.2023, 95(3):e20220672
  • Front Pharmacol.2018, 9:236
  • Life Sci.2019, 216:259-270
  • J Food Biochem.2021, 45(7):e13774.
  • Chem Biodivers.2023, 20(10):e202300741.
  • Journal of Apicultural Research2021, 60(1)
  • Front Pharmacol.2021, 12:690113.
  • Biomolecules.2020, 10(2):E184
  • Molecules. 2013, 18(7):7376-88
  • Rocaglaol

    Catalog No: CFN99609
    CAS No: 147059-46-9
    Price: Inquiry(manager@chemfaces.com)
    Desmethylrocaglamide

    Catalog No: CFN89458
    CAS No: 146408-78-8
    Price: Inquiry(manager@chemfaces.com)
    Rocaglamide

    Catalog No: CFN97339
    CAS No: 84573-16-0
    Price: Inquiry(manager@chemfaces.com)
    3'-Hydroxyrocaglamide

    Catalog No: CFN99875
    CAS No: 189322-67-6
    Price: Inquiry(manager@chemfaces.com)
    3'-Methoxyrocaglamide

    Catalog No: CFN99876
    CAS No: 189322-69-8
    Price: Inquiry(manager@chemfaces.com)
    Dehydroaglaiastatin

    Catalog No: CFN99660
    CAS No: 155595-93-0
    Price: Inquiry(manager@chemfaces.com)
    3'-Hydroxydehydroaglaiastatin

    Catalog No: CFN89448
    CAS No: 259143-58-3
    Price: Inquiry(manager@chemfaces.com)
    J Med Chem. 2009 Aug 27;52(16):5176-87.
    Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.[Pubmed: 19655762]
    Flavaglines constitute a family of natural anticancer compounds.
    METHODS AND RESULTS:
    We present here 3 (FL3), the first synthetic flavagline that inhibits cell proliferation and viability (IC(50) approximately 1 nM) at lower doses than did the parent compound, racemic Rocaglaol.
    US 20120101153 A1[P]. 2012.
    ROCAGLAOL DERIVATIVES AS CARDIOPROTECTANT AGENTS AND AS ANTINEOPLASTIC AGENTS[Reference: WebLink]

    METHODS AND RESULTS:
    The present invention discloses new Rocaglaol derivatives and the use of Rocaglaol derivatives to prevent or to limit the cardiotoxicity of an antineoplastic agent, in particular to prevent or to limit the apoptosis of cardiomyocytes induced by such agent.
    J Nat Prod. 1996 Jul;59(7):650-2.
    Cyclopentabenzofuran lignan protein synthesis inhibitors from Aglaia odorata.[Pubmed: 8759160 ]

    METHODS AND RESULTS:
    In the course of screening for Ras function inhibitors, Rocaglaol (1) and the related compounds, the known pyrimidinone (2) and the novel aglaiastatin (3), were isolated from a CHCI3 extract of the leaves of Aglaia odorata. The structure of 3 was elucidated as a novel cyclopentabenzofuran on the basis of its NMR spectroscopic data and by X-ray crystallographic analysis.
    CONCLUSIONS:
    These compounds (1-3) were potent inhibitors of the growth of K-ras-NRK cells, with IC50 values of 1-10 ng/mL, and induced normal morphology in K-ras-NRK cells at 10-30 ng/mL. They also specifically inhibited protein synthesis.Aglaiastatin (3) was slightly more potent than 1 and 2 in inhibiting cell growth. Aglaiastatin (3) reduced the amount of Ras, possibly by inhibiting its de novo synthesis.
    Anticancer Res. 2006 Mar-Apr;26(2A):947-52.
    Rocaglaol induces apoptosis and cell cycle arrest in LNCaP cells.[Pubmed: 16619491]

    METHODS AND RESULTS:
    Rocaglaol is a cytotoxic cyclopenta[b]benzofuran isolated from the bark of Aglaia crassinervia. It exhibited in vitro cytotoxic activity against Lu1, LNCaP and MCF-7 cells with ED50 values of 13.8, 23.0 and 9.2 nM, respectively. DAPI staining indicated that LNCaP cells treated with Rocaglaol underwent apoptosis. In order to determine whether Rocaglaol-induced apoptosis is mediated by the mitochondrial pathway, apoptosis-related mitochondrial-associated proteins were studied. Rocaglaol treatment induced Bax expression through 12 to 72 h of exposure, while Bcl-xl expression was slightly decreased through 48 h, and decreased more significantly by 72 h.Since Rocaglaol caused dose-dependent G2/M phase arrest of LNCaP cells as indicated by flow cytometric analysis, the protein levels of cell cycle-related genes were measured. Rocaglaol treatment (230 nM) did not change cyclin B after 24- to 60-h treatment. The expression of cdc2 was not changed and phospho-cdc2 (Tyr 15) increased after 36-, 48- and 60-h treatment. In addition, protein phosphatase Cdc25C, which functions as a mitotic activator by dephosphorylation of Cdc2, decreased in a time-dependent manner after Rocaglaol treatment.
    CONCLUSIONS:
    Taken together, these results suggest that Rocaglaol is a potent anticancer drug that induces apoptosis of LNCaP cells through the mitochondrial pathway and its G2/M-phase cell cycle arrest is associated with the down-regulation of Cdc25C and the dephosphorylation of Cdc2.
    Mol Pharmacol. 2005 May;67(5):1544-55.
    A synthetic derivative of the natural product rocaglaol is a potent inhibitor of cytokine-mediated signaling and shows neuroprotective activity in vitro and in animal models of Parkinson's disease and traumatic brain injury.[Pubmed: 15716464]
    Many acute and chronic neurodegenerative diseases are characterized by a localized inflammatory response and constitutive activation of the transcription factors nuclear factor-kappa B (NF-kappa B) and activator protein-1 (AP-1) as well as their upstream activating signaling cascades. Ample evidence indicates the implication of these processes in the pathogenesis of several diseases of the central nervous system.
    METHODS AND RESULTS:
    In this study, we show that a synthetic derivative of the natural product Rocaglaol (compound A) displays potent anti-inflammatory properties in human endothelial and murine glial cells in vitro. Compound A inhibited cytokine- and lipopolysaccharide-induced release of various cytokines/chemokines and of nitric oxide as well as expression of the adhesion molecule endothelial leukocyte adhesion molecule-1 and the inducible enzymes nitric-oxide synthase and cyclooxygenase-2. As shown by immunocytochemistry and immunoblotting, compound A inhibited NF-kappa B and AP-1 activity in mixed glial cultures. Compound A exhibited neuroprotective activity in vitro and in vivo. 1-Methyl-4-phenylpyridinium-induced damage of mesencephalic dopaminergic neurons was significantly decreased, and long-term treatment of 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine-injected mice with compound A significantly and dose-dependently reduced dopaminergic neuronal cell death. In addition, shortterm application of compound A to rats suffering from traumatic brain injury induced by subdural hematoma resulted in a significant reduction of the cerebral infarct volume.
    CONCLUSIONS:
    These results suggest that by inhibiting NF-kappa B and AP-1 signaling, compound A is able to reduce tissue inflammation and neuronal cell death, resulting in significant neuroprotection in animal models of neurodegeneration.
    Decursitin D

    Catalog No: CFN95002
    CAS No: 245446-61-1
    Price: $388/5mg
    Lonicerin

    Catalog No: CFN95055
    CAS No: 25694-72-8
    Price: $168/10mg
    3,7,25-Trihydroxycucurbita-5,23-dien-19-al

    Catalog No: CFN95150
    CAS No: 85372-65-2
    Price: $318/5mg
    Bergaptol-beta-glucopyranoside

    Catalog No: CFN95186
    CAS No: 131623-13-7
    Price: $318/10mg
    Corymboside

    Catalog No: CFN95292
    CAS No: 73543-87-0
    Price: $318/10mg
    Cuscutamine

    Catalog No: CFN95323
    CAS No: 122170-93-8
    Price: $318/5mg
    Tortoside B (Manglieside E)

    Catalog No: CFN95390
    CAS No: 190655-17-5
    Price: $413/5mg
    Kaempferol 3,5-O-diglucoside

    Catalog No: CFN95487
    CAS No: 205103-97-5
    Price: $318/10mg
    Mahuannin J

    Catalog No: CFN95533
    CAS No: N/A
    Price: $318/5mg
    1-O-Feruloylglucose

    Catalog No: CFN95596
    CAS No: 64625-37-2
    Price: $413/5mg